Deeg MA - Search Results

1

Ritonavir, triglycerides, and pancreatitis.

Perry RC, Cushing HE, Deeg MA, Prince MJ. Perry RC, et al. Among authors: deeg ma. Clin Infect Dis. 1999 Jan;28(1):161-2. doi: 10.1086/517194. Clin Infect Dis. 1999. PMID: 10028103 No abstract available.

2

Do n-3 fatty acids improve glucose tolerance and lipemia in diabetics?

Prince MJ, Deeg MA. Prince MJ, et al. Among authors: deeg ma. Curr Opin Lipidol. 1997 Feb;8(1):7-11. doi: 10.1097/00041433-199702000-00003. Curr Opin Lipidol. 1997. PMID: 9127704 Review.

3

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.

Ilag LL, Deeg MA, Costigan T, Hollander P, Blevins TC, Edelman SV, Konrad RJ, Ortmann RA, Pollom RK, Huster WJ, Zielonka JS, Prince MJ. Ilag LL, et al. Among authors: deeg ma. Diabetes Obes Metab. 2016 Feb;18(2):159-68. doi: 10.1111/dom.12584. Epub 2016 Jan 8. Diabetes Obes Metab. 2016. PMID: 26434665 Free PMC article. Clinical Trial.

4

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus^® Insulin Glargine.

Ilag LL, Costigan TM, Deeg MA, Pollom RK, Chang CL, Konrad RJ, Prince MJ. Ilag LL, et al. Among authors: deeg ma. Diabetes Ther. 2017 Jun;8(3):545-554. doi: 10.1007/s13300-017-0253-8. Epub 2017 Mar 30. Diabetes Ther. 2017. PMID: 28361463 Free PMC article.

5

Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.

Kelly RP, Garhyan P, Raddad E, Fu H, Lim CN, Prince MJ, Pinaire JA, Loh MT, Deeg MA. Kelly RP, et al. Among authors: deeg ma. Diabetes Obes Metab. 2015 Apr;17(4):414-22. doi: 10.1111/dom.12446. Epub 2015 Mar 2. Diabetes Obes Metab. 2015. PMID: 25656305 Clinical Trial.

6

Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.

Young EM, Considine RV, Sattler FR, Deeg MA, Buchanan TA, Degawa-Yamauchi M, Shankar S, Edmondson-Melançon H, Hernandez J, Dubé MP. Young EM, et al. Among authors: deeg ma. Cardiovasc Toxicol. 2004;4(2):179-86. doi: 10.1385/ct:4:2:179. Cardiovasc Toxicol. 2004. PMID: 15371633 Clinical Trial.

7

Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.

Dubé MP, Wu JW, Aberg JA, Deeg MA, Alston-Smith BL, McGovern ME, Lee D, Shriver SL, Martinez AI, Greenwald M, Stein JH; AIDS Clinical Trials Group A5148 Study Team. Dubé MP, et al. Among authors: deeg ma. Antivir Ther. 2006;11(8):1081-9. Antivir Ther. 2006. PMID: 17302378 Free PMC article. Clinical Trial.

8

Glucose and insulin regulate glycosylphosphatidylinositol-specific phospholipase D expression in islet beta cells.

Bowen RF, Raikwar NS, Olson LK, Deeg MA. Bowen RF, et al. Among authors: deeg ma. Metabolism. 2001 Dec;50(12):1489-92. doi: 10.1053/meta.2001.28087. Metabolism. 2001. PMID: 11735099

9

Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D.

Kurtz TA, Fineberg NS, Considine RV, Deeg MA. Kurtz TA, et al. Among authors: deeg ma. Metabolism. 2004 Feb;53(2):138-9. doi: 10.1016/j.metabol.2003.09.004. Metabolism. 2004. PMID: 14767861

10

Midportion antibodies stimulate glycosylphosphatidylinositol-specific phospholipase D activity.

Deeg MA, Bowen RF. Deeg MA, et al. Arch Biochem Biophys. 1999 Oct 15;370(2):278-84. doi: 10.1006/abbi.1999.1400. Arch Biochem Biophys. 1999. PMID: 10510287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters